𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends

✍ Scribed by Marie-Laure Couec; Nicolas André; Estelle Thebaud; Odile Minckes; Xavier Rialland; Nadège Corradini; Isabelle Aerts; Perrine Marec Bérard; Franck Bourdeaut; Pierre Leblond; on the behalf of the Comité Pharmacologie of the SFCE

Book ID
111697815
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
306 KB
Volume
59
Category
Article
ISSN
1545-5009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of a protracted irinoteca
Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma
✍ Gianni Bisogno; Riccardo Riccardi; Antonio Ruggiero; Giampaolo Arcamone; Arcange 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## Abstract ## BACKGROUND Irinotecan (CPT‐11) is a novel antineoplastic agent that takes effect by inhibiting topoisomerase I. The Italian Soft Tissue Sarcoma (STS) Committee performed a multiinstitutional Phase II study to evaluate its effect on STS. ## METHODS Over a 2‐year period between 2002

Hyperthermia for the treatment of patien
Hyperthermia for the treatment of patients with malignant germ cell tumors : A Phase I/II study in ten children and adolescents with recurrent or refractory tumors
✍ Rüdiger Wessalowski; Heidi Kruck; Hildegard Pape; Thomas Kahn; Reinhart Willers; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 3 views

waves in combination with platinum-based chemotherapy in ten children and 4 Institute of Statistics, Heinrich-Heine Univeradolescents with recurrent or refractory GCTs. sity, Du ¨sseldorf, Germany. ## RESULTS. Seven of ten patients with recurrent or refractory GCTs had objective responses. Of the